**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 7471**

**Columns:** **TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (2): Hepatitis C virus

**Eligibility of persons who inject drugs for treatment of hepatitis C virus** **infection**

Arain A *et al.* HCV infection management in PWID

Amber Arain, Geert Robaeys

**Amber Arain, Geert Robaeys,** Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk 3600, Belgium

**Amber Arain, Geert Robaeys,** Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek 3590, Belgium

**Geert Robaeys,** Department of Hepatology, UZ Leuven, Leuven 3000, Belgium

**Author contributions:** Arain A and Robaeys G contributed equally to this work; both authors performed the literature review and wrote the paper.

**Supported by** Limburg Clinical Research Program (LCRP) and by the Limburg Sterk Merk Foundation of Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital

**Correspondence to: Geert Robaeys, MD,** **PhD**, Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk 3600, Belgium. geert.robaeys@zol.be

**Telephone:** +32- 89-326505 **Fax:** +32-89-327916

**Received:** November 20, 2013 **Revised:** April 3, 2014

**Accepted:** May 19, 2014

**Published online:**

**Abstract**

In this decade, an increase is expected in end-stage liver disease and hepatocellular carcinoma, most commonly caused by hepatitis C virus (HCV) infection. Although people who inject drugs (PWID) are the major source for HCV infection, they were excluded from antiviral treatments until recently. Nowadays there is incontrovertible evidence in favor of treating these patients, and substitution therapy and active substance use are no longer contraindications for antiviral treatment. The viral clearance in PWID after HCV antiviral treatment with interferon or pegylated interferon combined with ribavirin is comparable to the viral clearance in non-substance users. Furthermore, multidisciplinary approaches to delivering treatment to PWID are advised, and their treatment should be considered on an individualized basis. To prevent the spread of HCV in the PWID community, recent active PWID are eligible for treatment in combination with needle exchange programs and substitution therapy. As the rate of HCV reinfection is low after HCV antiviral treatment, there is no need to withhold HCV treatment due to concerns about reinfection alone. Despite the advances in treatment efficacies and data supporting their success, HCV assessment of PWID and initiation of antiviral treatment remains low. However, the proportion of PWID assessed and treated for HCV is increasing, which can be further enhanced by understanding the barriers to and facilitators of HCV care. Removing stigmatization and implementing peer support and group treatment strategies, in conjunction with greater involvement by nurse educators/practitioners, will promote greater treatment seeking and adherence by PWID. Moreover, screening can be facilitated by noninvasive methods for detecting HCV antibodies and assessing liver fibrosis stages. Recently, HCV clearance has become a major endpoint in the war against drugs for the Global Commission on Drug Policy. This review highlights the most recent evidence concerning HCV infection and treatment strategies in PWID.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Hepatitis C virus; Persons who inject drugs; Methadone; Sustained viral response; Adherence

**Core tip:** People who inject drugs are considered to be the main reservoir for hepatitis C virus (HCV) infection. Accumulating evidence indicates that HCV-infected injection drug users can be successfully treated, and the earlier they are treated, the better the outcome. Therefore, in the future, the barriers for antiviral treatment for these individuals must be overcome. This topic highlight presents the most recent data concerning HCV infection and treatment of injection drug users.

Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

At the end of the nineties (1997) substance users were excluded from antiviral therapy against hepatitis C viral (HCV) infection[[1](#_ENREF_1)]. However, a great deal of evidence, accumulated between 2000 and 2005, showed a favorable outcome of HCV antiviral therapy in persons who inject drugs (PWID), and by 2009, they were no longer excluded from antiviral therapy in the American Association for the Study of Liver Diseases guidelines[[2](#_ENREF_2)]. Since then, the International Network on Hepatitis in Substance Users (www.inhsu.com) has organized forums at three international symposia distributing substantial information on the epidemiology and management of substance users infected with HCV, portions of which have been published in a supplemental issue of *Clinical Infectious Diseases*[[3](#_ENREF_3),[4](#_ENREF_4)]. Indeed, international recommendations for the treatment of HCV infection in PWID have recently been published[[5](#_ENREF_5)] and are being integrated into the European guidelines for HCV management[[6](#_ENREF_6)]. In addition, the eradication of HCV has become an actionable, evidence-based recommendation for constructive legal and policy reform of the Global Commission on Drug Policy[[7](#_ENREF_7)]. In view of the recent changes, this article aims to review and highlight new aspects concerning HCV infection in PWID.

**HCV INFECTION AMONG PWID**

HCV infection is one of the leading causes of chronic liver disease, and the prevalence of liver cirrhosis is increasing[[8](#_ENREF_8),[9](#_ENREF_9)]. In developed countries, 50 - 80% of HCV infection occurs in current and former PWID[[5](#_ENREF_5),[10](#_ENREF_10)]. The prevalence of HCV among PWID is approximately 65%, and can reach as high as 80% in long-term users[[11](#_ENREF_11),[12](#_ENREF_12)]. There are multiple strains of HCV, and PWID are generally infected with genotypes 1a, 1b and 3a[[13](#_ENREF_13)], though genotype 4d is common among PWID in Europe[[14](#_ENREF_14),[15](#_ENREF_15)], and genotype 6 is found in those from Southeast Asia[[5](#_ENREF_5),[16](#_ENREF_16),[17](#_ENREF_17)]. Factors associated with HCV infection in PWID include sex (female)[[18](#_ENREF_18)], ethnicity[[19](#_ENREF_19),[20](#_ENREF_20)], unstable housing[[21](#_ENREF_21)], frequent injection of cocaine[[18](#_ENREF_18),[22-24](#_ENREF_22)], imprisonment[[24](#_ENREF_24)], presence of injecting social-networks[[25](#_ENREF_25),[26](#_ENREF_26)] and sharing of injection equipment[[5](#_ENREF_5),[23](#_ENREF_23),[27](#_ENREF_27)].

***Disease progression and diagnosis***

Progression to chronic HCV (CHC) infection occurs in 75% of cases, with cirrhosis developing over two to three decades in 10 – 20%[[28-30](#_ENREF_28)]. HCV disease progression is slow and depends on the presence of several cofactors such as age[[9](#_ENREF_9)], continued moderate to heavy alcohol consumption[[31-33](#_ENREF_31)], HIV[[34-37](#_ENREF_34)], obesity[[38](#_ENREF_38),[39](#_ENREF_39)], insulin resistance[[40](#_ENREF_40),[41](#_ENREF_41)], daily cannabis[[42-44](#_ENREF_42)] and daily tobacco use[[45](#_ENREF_45)]. However, coffee consumption is associated with lower necro-inflammatory activity and less advanced fibrosis[[46-49](#_ENREF_46)]. There have been no reports of liver toxicity with heroin[[50](#_ENREF_50)] or methadone[[51](#_ENREF_51)], though buprenorphine occasionally increases transaminases[[52](#_ENREF_52)], and methylenedioxymetamphetamine (MDMA) rarely causes acute liver failure due to direct liver toxicity[[53-56](#_ENREF_53)].

The ageing population of PWID with CHC infection combined with low treatment uptake are leading to an increase in the burden of HCV related morbidity and mortality[[37](#_ENREF_37),[57-59](#_ENREF_57)]. In many countries where PWID are the largest population affected by HCV, 15%-30% of deaths are from drug-related causes, 20%-25% of deaths are from liver disease[[9](#_ENREF_9)], and liver failure, which increases over time, becomes the most common cause of death by the end of follow-up[[5](#_ENREF_5),[9](#_ENREF_9),[60-63](#_ENREF_60)].

There are various techniques available to assess liver disease progression and liver fibrosis, though the gold standard is diagnosis from liver biopsy[[2](#_ENREF_2)]. However, noninvasive methods have a greater acceptance among patients, including transient elastography (Fibroscan), which has been shown to enhance liver disease screening among PWID[[64](#_ENREF_64),[65](#_ENREF_65)] and acoustic radiation force impulse imaging.

**HCV TREATMENT**

***Treatment of PWID***

A treatment for HCV infection combines pegylated interferon (Peg-IFN) and ribavirin (RBV), which is safe and effective in PWID[[66-96](#_ENREF_66)] and has been recommended by international guidelines[[2](#_ENREF_2),[5](#_ENREF_5),[6](#_ENREF_6)]. In CHC treatment trials, the median sustained virologic response (SVR) rate among PWID is 54.3%, and is comparable to rates among non-PWID[[66](#_ENREF_66)]. In CHC patients infected with genotype 1, therapy with direct acting agents (DAA) combined with Peg-IFN and RBV enhances treatment response[[97-100](#_ENREF_97)], though the first cohort studies on the outcome of DAA therapy in substance users are underway. Studies evaluating drug interactions, including combinations of telaprevir and boceprevir with methadone[[101](#_ENREF_101)] and buprenorphine[[102](#_ENREF_102)], found no clinically important interactions[[49](#_ENREF_49)]. Furthermore, there is currently no indication that history of substance use, substitution therapy or active substance use influences SVR[[103-105](#_ENREF_103)].

 It is important to note that PWID are typically younger[[82](#_ENREF_82)], are infected with genotype 3 and have mild liver disease[[71](#_ENREF_71)] compared to non-substance users, which are characteristics associated with favorable HCV treatment outcome[[5](#_ENREF_5)]. However, treatment of HCV-infected PWID is complicated by their complex social, medical and psychiatric comorbidities[[106](#_ENREF_106)], lack of HCV knowledge and inaccurate perceptions of patients[[107-110](#_ENREF_107)]. Other factors that may prevent HCV-infected PWID from seeking treatment include age[[111](#_ENREF_111)], being of an ethnic minority[[111](#_ENREF_111)], former or ongoing drug[[112-114](#_ENREF_112)] and alcohol use[[111](#_ENREF_111),[112](#_ENREF_112)], advanced liver disease[[113](#_ENREF_113)], comorbid diseases[[111-114](#_ENREF_111)], psychiatric disease[[111-113](#_ENREF_111)] and opioid substitution treatment[[5](#_ENREF_5),[112](#_ENREF_112)]. In order to overcome these barriers, recent guidelines recommend linking PWID to social support services and peer support by providing pre-therapeutic education and counseling about the impact of alcohol, cannabis, tobacco and drug use on their life[[5](#_ENREF_5)]. HCV treatment for PWID should be considered on an individualized basis and delivered within a multidisciplinary team setting[[5](#_ENREF_5)].

***Treatment of active PWID***

Acceptable treatment outcomes, with a low rate of reinfection (2.4 per 100 patient years), can be achieved in actively injecting PWID, as they show high adherence to treatment (82%)[[115](#_ENREF_115)]. The first randomized controlled trial among active PWID reported that the delivery of directly observed therapy (DOT) with Peg-IFN and self-administered (SA) RBV within multidisciplinary community health centers was an effective strategy for the treatment of HCV with a low reinfection rate[[116](#_ENREF_116)]. In this trial nearly 80% completed treatment, two-thirds responded to therapy, and drug use at the time of treatment initiation was not associated with reduced SVR. Additional studies have confirmed that SVR rates are not affected, with an SVR rate of 55.5% among treated PWID that is comparable to rates of 54% and 56% recorded in Peg-IFN plus RBV registration trials[[117](#_ENREF_117),[118](#_ENREF_118)].

***Treatment completion and adherence among PWID***

Recently, a meta-analysis of 32 studies by Dimova *et al*[[119](#_ENREF_119)]found that the treatment completion rate among PWID was 83.4%. Moreover, it has been shown that there is no difference between PWID and non-PWID with respect to treatment adherence[[71](#_ENREF_71),[88](#_ENREF_88)]. However, among studies that compared addiction-treated and untreated PWID during HCV therapy, the higher the proportion of addiction-treated patients, the higher the HCV treatment completion rate. Thus, the assessment of a patient’s social circumstances and the availability of support (in addition to injection behavior) are important aspects to consider when starting HCV treatment.

 Review of the literature shows that seven studies have evaluated antiviral treatment adherence in patients with a history of drug use[[90](#_ENREF_90),[91](#_ENREF_91),[96](#_ENREF_96),[120-123](#_ENREF_120)]. These studies defined adherence differently, and do not present a consensus regarding what adequate treatment adherence is. These studies defined adherence as receiving ≥80% of expected Peg-IFN and RBV dosage for ≥ 80% of the expected therapy duration[[91](#_ENREF_91),[96](#_ENREF_96),[120](#_ENREF_120),[121](#_ENREF_121)], presentation at ≥ 80% of visitation dates[[123](#_ENREF_123)], fulfillment of the treatment schedule and 6-month follow-up[[90](#_ENREF_90)], or being >80% compliant with the planned cumulative doses of Peg-IFN, RBV and the prescribed duration of treatment[[122](#_ENREF_122)]. One study reported that patients attending 80% of addiction care sessions demonstrated an adherence of more than 80%[[91](#_ENREF_91)]. In this study, the consumption of crack and heroin was significantly associated with reduced compliance, with users being five times more likely not to comply. Three of the reports studied adherence in PWID on opioid substitution therapy[[96](#_ENREF_96),[120](#_ENREF_120),[122](#_ENREF_122)]. Adherence rates of 68%[[120](#_ENREF_120)] and 85%[[96](#_ENREF_96)] were reported for the total population. However, when DOT and SA groups were compared, 67 and 63% of patients were > 80% compliant with Peg-IFN treatment, 50 and 54% were > 80% compliant with RBV treatment, and 67 and 63% were > 80% compliant with the prescribed duration of treatment, respectively[[122](#_ENREF_122)]. Former drug users also demonstrate an excellent adherence to therapy[[121](#_ENREF_121)]. In a study evaluating adherence in patients with a history of intravenous drug use, 65% of the 175 patients were considered to be adherent to therapy, as they completed the recommended treatment schedule and attended the follow-up period[[90](#_ENREF_90)]. An adherence rate of 92% was reported in patients on heroin maintenance[[123](#_ENREF_123)]. Only three[[90](#_ENREF_90),[96](#_ENREF_96),[120](#_ENREF_120)] of these seven studies evaluated the relationship between adherence and the response to treatment and found that SVR rates were significantly higher in adherent patients compared to non-adherent patients. In conclusion, adherence during the antiviral treatment is associated with better treatment outcome.

***Barriers for HCV antiviral management in PWID***

There are barriers for HCV care and management that are present at multiple levels. At the level of government, competing national priorities can impede the healthcare system, and promote a lack of awareness of HCV infection. At the level of the clinical management team, there is often a lack of experience and collaborative networking. There is also a paucity of treatment settings adapted for the needs of PWID[[124](#_ENREF_124),[125](#_ENREF_125)]. The lack of HCV knowledge and the limited infrastructure for treatment in addiction and primary care centers prevents them from treating PWID[[106](#_ENREF_106),[126](#_ENREF_126),[127](#_ENREF_127)]. Finally, the patients themselves are an obstacle, and they may not seek treatment because of insufficient awareness of HCV, competing life priorities, fear of side effects, anxieties of being stigmatized, *etc.*[[107](#_ENREF_107),[110](#_ENREF_110),[128-132](#_ENREF_128)].

 The stigmatization of HCV patients is an important barrier to receiving HCV care, a topic which has been discussed in great detail by Treloar *et al*[[133](#_ENREF_133)]. Patients are stigmatized because of their drug use and their HCV infection. Stigmas perceived by PWID can persist even after reducing or ceasing drug use[[134](#_ENREF_134)], and can have a negative effect on their mental and physical health[[135-137](#_ENREF_135)]. The stigma associated with HCV infection negatively impacts the prevention of transmission, the seeking of and adherence to treatment and the overall quality of life[[138-142](#_ENREF_138)]. Patients can be stigmatized by family members or partners[[139](#_ENREF_139)], the public[[143](#_ENREF_143)] and most commonly by healthcare settings[[133](#_ENREF_133)]. However, trust in healthcare professionals can impact health-related patient behavior, and improving this trust may reduce the associated stigmas and create a willingness to use health services and adherence to treatment[[133](#_ENREF_133),[144](#_ENREF_144)].

**STRATEGIES AND TREATMENT MODELS TO IMPROVE HCV CARE IN PWID**

The HCV care of patients can be improved by treating comorbidities, side effects and providing all the necessary support. A multidisciplinary approach to HCV treatment can be provided by utilizing community-based and hospital-based clinics, as well as opioid substitution treatment and drug detoxification centers[[67](#_ENREF_67),[92](#_ENREF_92),[145-148](#_ENREF_145)]. For example, the placement of an internist addiction medicine specialist from an opioid substitution program in a hepatitis clinic proved to be an effective and efficient way to deliver HCV evaluation and treatment to patients in opioid substitution therapy[[72](#_ENREF_72)]. A meta-analysis by Dimova *et al*[95] identified “treatment of addiction during HCV therapy” as a parameter leading to higher treatment completion[[119](#_ENREF_119)]. Integrating HCV care into both primary addiction care and into general practices has also proved to be effective[[146](#_ENREF_146),[149-151](#_ENREF_149)].

 An overview on management of mental health problems in HCV patients with drug addictions by Schaefer *et al*[[152](#_ENREF_152)] indicated that PWID do not have an increased risk of developing major or severe depression during HCV antiviral treatment with IFN. However, it is recommended to make case-by-case decisions and provide antidepressant treatment when needed, especially for patients who are depressed or have a history of depression. It was also shown that the integration of psychologist-led interventions into a hepatology unit increased HCV treatment eligibility in an underserved population with mental health and substance abuse comorbidities[[153](#_ENREF_153)]. This trial by Evon *et al*. enrolled 101 HCV patients who were deferred from antiviral therapy owing to mental health or substance abuse. The integrated care intervention group received counseling and case management, including monthly phone and in-person intervention sessions with the hepatology psychologist for up to nine months. In an intent-to-treat analysis, 42% of intervention group participants became eligible for therapy compared to 18% of standard care participants. Additionally, a study by Reimer *et al*[[154](#_ENREF_154)] found that CHC patients (infected with genotype 1/4) who attended at least five psychoeducation sessions showed significantly higher SVR rates.

 The involvement of nurse educators/practitioners can greatly improve HCV management. Systematic consultations with a nurse after each medical visit enhanced treatment adherence (74.0% *vs* 62.8%) and increased SVR rates (38.2% *vs* 24.8%) compared to a conventional follow-up[[155](#_ENREF_155)]. Psychotherapy provided by a psychiatric nurse along with administration of psychopharmacological medication in an HCV clinic can significantly improve assessment and treatment uptake[[156](#_ENREF_156)]. A nurse-led model of HCV assessment and treatment developed by Lloyd *et al*[[157](#_ENREF_157)] involved a substantial task transfer from specialist physicians to trained nurses. In this two-year study, 108 patients were treated, including 85 (79%) triaged for specialist review conducted by telemedicine only. Antiviral treatment delivery was found to be both safe (7% treatment discontinuations, 12% serious adverse events) and efficacious (69% SVR for those with completed datasets and 44% by intention-to-treat analysis).

 Opioid substitution clinics, which provide substance abuse treatment, have begun to integrate DOT of Peg-IFN and/or RBV in collaboration with a secondary or tertiary setting that is providing the HCV care with favorable results[[70](#_ENREF_70),[86](#_ENREF_86)]. Grebely *et al*[[86](#_ENREF_86)] observed an end of treatment response in 67% of the subjects despite ongoing drug use in 75% of patients during treatment with an SVR rate of 55%[[85](#_ENREF_85)]. An SVR rate of 98% was reported in a similar study evaluating the efficacy and tolerability of DOT with Peg-IFN and RBV in 49 opioid-addicted injection drug users[[70](#_ENREF_70)].

 Other models of HCV treatment incorporating peer support and group treatment are very effective. In these models, peers stimulate each other in developing positive and healthy behaviors, and have been shown to increase the assessment and treatment of HCV[[67](#_ENREF_67),[158-162](#_ENREF_158)]. The group treatment model used by Stein *et al*[[158](#_ENREF_158)] was found to be acceptable by all patients, and no patient expressed discomfort with receiving medical care in a group setting. Of the first 27 patients who initiated the group treatment, 42% achieved an SVR. Results from the nonprofit community clinic OASIS indicate that the peer-based model is successful at engaging, educating and treating a diverse spectrum of chaotic drug users[[162](#_ENREF_162)]. This model allowed for successful treatment of more challenging HCV patients, including those with active drug use, mental illness and psychosocial instability. In a clinic with only one physician and one or two physician assistants, almost 3500 people were tested and several hundred were treated. The peer-based models show encouraging results not only in assessment and treatment but also in the prevention of HCV[[163-165](#_ENREF_163)].

 Current knowledge suggests that as no one model meets all the needs of a heterogeneous patient population, offering a range of various settings is the best way to reach the greatest needs of PWID. Close collaboration of all involved health professionals is crucial for every model to be successful. Furthermore, acceptance of the individual circumstances of PWID will determine the level of success of any model of HCV management, rather than rigid exclusion criteria[[159](#_ENREF_159)].

**COST-EFFECTIVENESS OF HCV MANAGEMENT IN PWID**

As the majority of new HCV infections occur in PWID, successful screening and treatment of this population will prevent new cases and lower costs associated with disease progression[[166-168](#_ENREF_166)]. Martin *et al*[[166](#_ENREF_166)] determined that HCV case finding among PWID by offering dried blood spot testing in specialist addiction services or prisons as compared to using venipuncture was cost-effective. However, the cost-effectiveness of prison case-finding interventions depends on adequate continuity of care with the community after release from prison. Another modeling study by this group explored the feasibility of DAA-based HCV treatment as prevention and indicated that scaling-up treatment could lead to substantial reductions in HCV prevalence[[167](#_ENREF_167)]. However, the cost of treatment may limit its scaling-up, thus, treatment cost also needs to be addressed.

**HCV IN CORRECTIONAL SETTINGS**

The prevalence of HCV is much higher in prison inmates than in the general population, ranging from 30%-40%[[169](#_ENREF_169)]. Furthermore, there is a clear association between the HCV prevalence and inmate history of injection drug use, sex (female) and tattooing[[170](#_ENREF_170)]. Thus, prisons may be important settings for health intervention such as screening, diagnosis, prevention and treatment of HCV infection. Screening rates could be improved in correctional settings with the introduction of dried blood spot testing[[171](#_ENREF_171)]. SVR rates for prison patients treated with a combination therapy are comparable to those observed in non-inmate patients, therefore, antiviral treatment in prison may be cost-effective[[172](#_ENREF_172)]. Prevention and treatment could also be improved if more programs were developed to ensure continuity of care and follow-up upon release or transfer from prisons[[173](#_ENREF_173)].

**REINFECTION AFTER SUCCESSFUL HCV TREATMENT**

Frequent testing and viral sequencing are necessary to discriminate between relapse and reinfection in high-risk populations. Guidelines recommend monitoring for HCV reinfection with annual HCV RNA assessments in PWID with ongoing risk behaviors[[5](#_ENREF_5)]. As ongoing injection drug use after treatment is common, harm reduction and counseling about the risk of reinfection is important[[174](#_ENREF_174)]. However, rates of HCV reinfection among PWID is low, at approximately 1%-5%[[174](#_ENREF_174)], even among persons who continue injection drug use during and after treatment. A recent meta-analysis by Aspinall *et al*[[115](#_ENREF_115)] reported that the pooled HCV reinfection risk was 2.4 per 100 person-years, suggesting that HCV treatment should not be withheld due to concerns about reinfection alone. Moreover, HCV reinfection after treatment may clear spontaneously[[174](#_ENREF_174)].

**PREVENTION OF HCV TRANSMISSION**

HCV prevention strategies in PWID have been described in detail by Page *et al.* who state that it is essential to promote access to sterile injection materials (increased needle/syringe distribution) in combination with strategies to encourage injection cessation, opioid substitution treatment, interventions to reduce risk behaviors, rapid and accurate HCV testing and diagnosis and increased access and initiation of HCV treatment[[175](#_ENREF_175)]. The impact and feasibility of treatment as a prevention strategy could be substantially increased by future IFN-free DAA treatment regimes with enhanced efficacy (> 90%), once-daily oral-only dosing, reduced toxicity and shortened treatment duration (about 12 wk)[[176](#_ENREF_176)].

**IMPROVEMENTS IN HCV CARE FOR THE FUTURE**

There are several changes that can be made to improve the treatment and management of HCV care. Firstly, patients should be treated irrespective of their liver fibrosis stage, which is not the case at this moment in many countries, as a fibrosis stage of at least F2 is a prerequisite to obtain antiviral treatment. Secondly, the risk of reinfection should be an indication for treatment, as people at risk of reinfection are also the ones most likely to further spread the virus. Thirdly, treatment could be increased among PWID by decriminalizing drug use and reducing other barriers to HCV care, such as high treatment costs[[177](#_ENREF_177)].

 Only five countries offer systematic annual screening for infectious diseases to all PWID according to the European Liver Patients Association, and only two countries have governmental funding for a national hepatitis strategy[[178](#_ENREF_178)]. Thus, systematic screening for HCV infection in PWID needs to be developed. Oral IFN-free regimens are approaching 100% efficacy, but real world effectiveness will remain very low without fundamental change in health care delivery[[178](#_ENREF_178)]. An increase in instrumental support provided by healthcare professionals is needed. As suggested by the Global Commission on Drug Policy, the war against drugs must be substituted with “drug policy success measurement” indicators that have real meaning in communities, such as reduced rates of HCV infection, fewer overdose deaths, reduced drug market violence, fewer individuals incarcerated and lowered rates of problematic substance abuse[[7](#_ENREF_7)].

**CONCLUSION**

PWID are the major reservoir for infectious HCV, and as a result, an increase is expected in compensated and decompensated liver disease and hepatocellular carcinoma in this population. At the end of the nineties, PWID were excluded from antiviral therapy in official guidelines, but nowadays there is incontrovertible evidence supporting treatment of these patients. The guidelines recommend that these patients be considered on an individualized basis for antiviral therapy and that therapy should be provided within a multidisciplinary team setting. Indeed, HCV clearance has recently become a major endpoint in the war against drugs for the Global Commission on Drug Policy.

Although the outcome of antiviral treatment and treatment compliance in PWID is comparable to non-PWID, there are still several barriers to accessing care. By understanding the barriers to and facilitators of HCV care, the proportion of PWID assessed and treated for HCV is being increased. HCV screening has been facilitated by noninvasive methods for detecting HCV antibodies and stage of liver fibrosis. Treatment has been facilitated by implementing various strategies and models of HCV care that include the integration of psychologist-led interventions, involvement of nurse practitioners and DOT and peer support models. Despite the high prevalence of HCV-infected patients and the favorable outcome of antiviral treatment in custodial settings, the uptake for HCV management needs to be increased substantively. Eligibility of recently active PWID for treatment in combination with needle exchange programs and substitution therapy can help to prevent the spread of HCV in the PWID community. Although HCV screening and treatment in PWID is shown to be cost-effective, the assessment of PWID for antiviral treatment remains low. Despite the irrefutable evidence in favor of treating PWID, the management of their care has yet to be initiated in some countries, and optimized in many others.

**REFERENCES**

1 National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. *Hepatology* 1997; **26**: 2S-10S [PMID: 9305656 DOI: 10.1002/hep.510260701]

2 **Ghany MG**, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009; **49**: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]

3 **International Network on Hepatitis in Substance Users.** A supplement to Clinical infectious Diseases. Prevention and management of hepatitis C virus infection among people who inject drugs: Moving the agenda forward. *Clin Infect Dis* 2013; **57** (Suppl 2) [DOI: 10.1093/cid/cit330]

4 **Grebely J**, Bruggmann P, Backmund M, Dore GJ. Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. *Clin Infect Dis* 2013; **57** Suppl 2: S29-S31 [PMID: 23884062 DOI: 10.1093/cid/cit264]

5 **Robaeys G**, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Clin Infect Dis* 2013; **57** Suppl 2: S129-S137 [PMID: 23884061 DOI: 10.1093/cid/cit302]

6 **European Association for the Study of the Liver.** EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol* 2011; **55**: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]

7 **The Global Commission on Drug Policy.** The negative impact of the war on drugs on public health: the hidden hepatitis C epidemic 2013. Available from: http: //www.globalcommissionondrugs.org/hepatitis/.

8 **Health Protection Agency.** Hepatitis C in the UK, Figure 15, 2013 Report. Available from: http: //www.hpa.org.uk/webc/HPAwebFile/HPAweb\_C/1317139502302.

9 **Grebely J**, Dore GJ. What is killing people with hepatitis C virus infection? *Semin Liver Dis* 2011; **31**: 331-339 [PMID: 22189973 DOI: 10.1055/s-0031-1297922]

10 **Shepard CW**, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005; **5**: 558-567 [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4]

11 **Hagan H**, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. *Am J Epidemiol* 2008; **168**: 1099-1109 [PMID: 18849303 DOI: 10.1093/aje/kwn237]

12 **Nelson PK**, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; **378**: 571-583 [PMID: 21802134 DOI: 10.1016/S0140-6736(11)61097-0]

13 **Pybus OG**, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virus epidemic among injecting drug users. *Infect Genet Evol* 2005; **5**: 131-139 [PMID: 15639745 DOI: 10.1016/j.meegid.2004.08.001]

14 **van Asten L**, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, Rezza G, Broers B, Robertson JR, Brettle RP, McMenamin J, Prins M, Cochrane A, Simmonds P, Coutinho RA, Bruisten S. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. *J Infect Dis* 2004; **189**: 292-302 [PMID: 14722895 DOI: JID30925]

15 **de Bruijne J**, Schinkel J, Prins M, Koekkoek SM, Aronson SJ, van Ballegooijen MW, Reesink HW, Molenkamp R, van de Laar TJ. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. *J Clin Microbiol* 2009; **47**: 3832-3838 [PMID: 19794040 DOI: 10.1128/JCM.01146-09]

16 **Sievert W**, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. *Liver Int* 2011; **31** Suppl 2: 61-80 [PMID: 21651703 DOI: 10.1111/j.1478-3231.2011.02540.x]

17 **Antaki N**, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. *Liver Int* 2010; **30**: 342-355 [PMID: 20015149 DOI: 10.1111/j.1478-3231.2009.02188.x]

18 **Patrick DM**, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, Strathdee SA, Currie SL, Schechter MT, O'Shaughnessy MV. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. *CMAJ* 2001; **165**: 889-895 [PMID: 11599327]

19 **Maher L**, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? *Aust N Z J Public Health* 2007; **31**: 30-35 [PMID: 17333606 DOI: 10.1111/j.1753-6405.2007.00007.x]

20 **Miller CL**, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, Montaner JS, Schechter MT. The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. *J Acquir Immune Defic Syndr* 2004; **36**: 743-749 [PMID: 15167294 DOI: 10.1097/00126334-200406010-00012]

21 **Kim C**, Kerr T, Li K, Zhang R, Tyndall MW, Montaner JS, Wood E. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. *BMC Public Health* 2009; **9**: 270 [PMID: 19640297 DOI: 1471-2458-9-270]

22 **Miller CL**, Johnston C, Spittal PM, Li K, Laliberté N, Montaner JS, Schechter MT. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. *Hepatology* 2002; **36**: 737-742 [PMID: 12198668 DOI: 10.1053/jhep.2002.35065]

23 **Roy E**, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, Rochefort J, Claessens C. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. *Int J STD AIDS* 2007; **18**: 23-27 [PMID: 17326858 DOI: 10.1258/095646207779949880]

24 **Bruneau J**, Daniel M, Kestens Y, Abrahamowicz M, Zang G. Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study. *Int J Drug Policy* 2010; **21**: 477-484 [PMID: 20541926 DOI: S0955-3959(10)00075-7]

25 **Aitken C,** Lewis J, Hocking J, Bowden DS, Hellard M. Does Information about IDUs' Injecting Networks Predict Exposure to the Hepatitis C Virus? *Hepatitis Monthly* 2009; **9**: 17-23

26 **Sacks-Davis R**, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M. Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. *PLoS One* 2012; **7**: e47335 [PMID: 23110068 DOI: 10.1371/journal.pone.0047335]

27 **Hahn JA**, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. *J Infect Dis* 2002; **186**: 1558-1564 [PMID: 12447730 DOI: 10.1086/345554]

28 **Freeman AJ**, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001; **34**: 809-816 [PMID: 11584380 DOI: 10.1053/jhep.2001.27831]

29 **Thein HH**, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology* 2008; **48**: 418-431 [PMID: 18563841 DOI: 10.1002/hep.22375]

30 **Seeff LB**. The history of the "natural history" of hepatitis C (1968-2009). *Liver Int* 2009; **29** Suppl 1: 89-99 [PMID: 19207971 DOI: LIV1927]

31 **Ostapowicz G**, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. *Hepatology* 1998; **27**: 1730-1735 [PMID: 9620350 DOI: S0270913998002560]

32 **Harris DR**, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, Seeff LB. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Ann Intern Med* 2001; **134**: 120-124 [PMID: 11177315 DOI: 200101160-00012]

33 **Hutchinson SJ**, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. *Clin Gastroenterol Hepatol* 2005; **3**: 1150-1159 [PMID: 16271348 DOI: S1542-3565(05)00407-6]

34 **Graham CS**, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis* 2001; **33**: 562-569 [PMID: 11462196 DOI: CID001179]

35 **Ragni MV**, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. *J Infect Dis* 2001; **183**: 1112-1115 [PMID: 11237838 DOI: JID000879]

36 **Thomas DL**, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, Cheung L, Nelson KE. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. *J Infect Dis* 1996; **174**: 690-695 [PMID: 8843204 DOI: 10.1093/infdis/174.4.690]

37 **Grebely J**, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, Dore GJ, Tyndall MW. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. *J Viral Hepat* 2011; **18**: 32-41 [PMID: 20196806 DOI: JVH1279]

38 **Hourigan LF**, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* 1999; **29**: 1215-1219 [PMID: 10094967 DOI: S0270913999001858]

39 **Ortiz V**, Berenguer M, Rayón JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol* 2002; **97**: 2408-2414 [PMID: 12358265 DOI: 10.1111/j.1572-0241.2002.05995.x]

40 **Monto A**, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. *Hepatology* 2002; **36**: 729-736 [PMID: 12198667 DOI: S0270913902000800]

41 **Ratziu V**, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. *J Hepatol* 2003; **39**: 1049-1055 [PMID: 14642625 DOI: S0168827803004562]

42 **Hézode C**, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. *Hepatology* 2005; **42**: 63-71 [PMID: 15892090 DOI: 10.1002/hep.20733]

43 **Ishida JH**, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA. Influence of cannabis use on severity of hepatitis C disease. *Clin Gastroenterol Hepatol* 2008; **6**: 69-75 [PMID: 18166478 DOI: 10.1016/j.cgh.2007.10.021]

44 **Hézode C**, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. *Gastroenterology* 2008; **134**: 432-439 [PMID: 18242211 DOI: 10.1053/j.gastro.2007.11.039]

45 **Mallat A**, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic hepatitis C. *J Hepatol* 2008; **48**: 657-665 [PMID: 18279998 DOI: 10.1016/j.jhep.2008.01.004]

46 **Costentin CE**, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A, Hézode C. Association of caffeine intake and histological features of chronic hepatitis C. *J Hepatol* 2011; **54**: 1123-1129 [PMID: 21145804 DOI: 10.1016/j.jhep.2010.08.027]

47 **Modi AA**, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH. Increased caffeine consumption is associated with reduced hepatic fibrosis. *Hepatology* 2010; **51**: 201-209 [PMID: 20034049 DOI: 10.1002/hep.23279]

48 **Freedman ND**, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. *Gastroenterology* 2011; **140**: 1961-1969 [PMID: 21376050 DOI: 10.1053/j.gastro.2011.02.061]

49 **Mauss S**, Klinker H. Drug-drug interactions in the treatment of HCV among people who inject drugs. *Clin Infect Dis* 2013; **57** Suppl 2: S125-S128 [PMID: 23884060 DOI: 10.1093/cid/cit299]

50 **Rehm J**, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994-2000. *Drug Alcohol Depend* 2005; **79**: 137-143 [PMID: 16002023 DOI: 10.1016/j.drugalcdep.2005.01.005]

51 **Kreek MJ**, Dodes L, Kane S, Knobler J, Martin R. Long-term methadone maintenance therapy: effects on liver function. *Ann Intern Med* 1972; **77**: 598-602 [PMID: 4629927 DOI: 10.7326/0003-4819-77-4-598]

52 **Petry NM**, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. *Am J Addict* 2000; **9**: 265-269 [PMID: 11000922 DOI: 10.1080/10550490050148099]

53 **Andreu V**, Mas A, Bruguera M, Salmerón JM, Moreno V, Nogué S, Rodés J. Ecstasy: a common cause of severe acute hepatotoxicity. *J Hepatol* 1998; **29**: 394-397 [PMID: 9764985 DOI: 10.1016/S0168-8278(98)80056-1]

54 **Lange-Brock N**, Berg T, Müller AR, Fliege H, Neuhaus P, Wiedenmann B, Klapp BF, Mönnikes H. [Acute liver failure following the use of ecstasy (MDMA)]. *Z Gastroenterol* 2002; **40**: 581-586 [PMID: 12297982 DOI: 10.1055/s-2002-33416]

55 **Refstad S**. Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects. *Acta Anaesthesiol Scand* 2003; **47**: 1298-1299 [PMID: 14616331 DOI: 10.1046/j.1399-6576.2003.00245.x]

56 **Turillazzi E**, Riezzo I, Neri M, Bello S, Fineschi V. MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings. *Curr Pharm Biotechnol* 2010; **11**: 500-509 [PMID: 20420577 DOI: 10.2174/138920110791591481]

57 **Darke S**, Kaye S, Duflou J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. *Addiction* 2006; **101**: 1771-1777 [PMID: 17156176 DOI: ADD1601]

58 **Sherman M**, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschênes M. Management of chronic hepatitis C: consensus guidelines. *Can J Gastroenterol* 2007; **21** Suppl C: 25C-34C [PMID: 17568824]

59 **Kielland KB**, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. *J Hepatol* 2013; **58**: 31-37 [PMID: 22960427 DOI: 10.1016/j.jhep.2012.08.024]

60 **Gibson A**, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid-dependent people: cohort study. *Addiction* 2011; **106**: 2186-2192 [PMID: 21749525 DOI: 10.1111/j.1360-0443.2011.03575.x]

61 **Darke S**, Kaye S, Duflou J. Systemic disease among cases of fatal opioid toxicity. *Addiction* 2006; **101**: 1299-1305 [PMID: 16911729 DOI: 10.1111/j.1360-0443.2006.01495.x]

62 **Degenhardt L**, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. *Addiction* 2011; **106**: 32-51 [PMID: 21054613 DOI: 10.1111/j.1360-0443.2010.03140.x]

63 **Amin J**, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. *Lancet* 2006; **368**: 938-945 [PMID: 16962883 DOI: 10.1016/S0140-6736(06)69374-4]

64 **Moessner BK**, Jørgensen TR, Skamling M, Vyberg M, Junker P, Pedersen C, Christensen PB. Outreach screening of drug users for cirrhosis with transient elastography. *Addiction* 2011; **106**: 970-976 [PMID: 21182552 DOI: 10.1111/j.1360-0443.2010.03246.x]

65 **Foucher J**, Reiller B, Jullien V, Léal F, di Cesare ES, Merrouche W, Delile JM, de Lédinghen V. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. *J Viral Hepat* 2009; **16**: 121-131 [PMID: 19175876 DOI: 10.1111/j.1365-2893.2008.01050.x]

66 **Hellard M**, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. *Clin Infect Dis* 2009; **49**: 561-573 [PMID: 19589081 DOI: 10.1086/600304]

67 **Grebely J**, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S, Duncan F, Conway B. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. *Eur J Gastroenterol Hepatol* 2010; **22**: 270-277 [PMID: 20425880 DOI: 10.1097/MEG.0b013e32832a8c4c]

68 **Lindenburg CE**, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, Casteelen G, van Santen G, van den Berg CH, Coutinho RA, Prins M, Weegink CJ. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. *Eur J Gastroenterol Hepatol* 2011; **23**: 23-31 [PMID: 21042221 DOI: 10.1097/MEG.0b013e328340c451]

69 **Dore GJ**, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. *Gastroenterology* 2010; **138**: 123-35.e1-2 [PMID: 19782085 DOI: S0016-5085(09)01660-6]

70 **Waizmann M**, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. *J Subst Abuse Treat* 2010; **38**: 338-345 [PMID: 20362408 DOI: S0740-5472(10)00029-2]

71 **Melin P**, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, Marcellin P, Cacoub P. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. *Eur J Gastroenterol Hepatol* 2010; **22**: 1050-1057 [PMID: 20351554 DOI: 10.1097/MEG.0b013e328338d9aa]

72 **Martinez AD**, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, Talal AH. Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. *J Viral Hepat* 2012; **19**: 47-54 [PMID: 21129131 DOI: 10.1111/j.1365-2893.2010.01411.x]

73 **Backmund M**, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. *Hepatology* 2001; **34**: 188-193 [PMID: 11431750 DOI: 10.1053/jhep.2001.25882]

74 **Dalgard O**. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. *Clin Infect Dis* 2005; **40** Suppl 5: S336-S338 [PMID: 15768344 DOI: CID34655]

75 **Sylvestre DL**. Treating hepatitis C in methadone maintenance patients: an interim analysis. *Drug Alcohol Depend* 2002; **67**: 117-123 [PMID: 12095661 DOI: 10.1016/S0376-8716(02)00010-8]

76 **Neri S**, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, Bordonaro F, Pulvirenti D, Italiano C, Caruso L. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. *Clin Ther* 2002; **24**: 1627-1635 [PMID: 12462291 DOI: 10.1016/S0149-2918(02)80065-0]

77 **Schaefer M**, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. *Hepatology* 2003; **37**: 443-451 [PMID: 12540795 DOI: 10.1053/jhep.2003.50031]

78 **Van Thiel DH**, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. *Am J Gastroenterol* 2003; **98**: 2281-2288 [PMID: 14572580 DOI: S0002927003007081]

79 **Mauss S**, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. *Hepatology* 2004; **40**: 120-124 [PMID: 15239094 DOI: 10.1002/hep.20279]

80 **Matthews G**, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. *Clin Infect Dis* 2005; **40** Suppl 5: S325-S329 [PMID: 15768342 DOI: 10.1086/427448]

81 **Sylvestre DL**, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. *J Subst Abuse Treat* 2005; **29**: 159-165 [PMID: 16183464 DOI: S0740-5472(05)00133-9]

82 **Robaeys G**, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. *Eur J Gastroenterol Hepatol* 2006; **18**: 159-166 [PMID: 16394797 DOI: 10.1097/00042737-200602000-00008]

83 **Jeffrey GP**, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, Hulse G, O'Neil G. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. *Hepatology* 2007; **45**: 111-117 [PMID: 17187435 DOI: 10.1002/hep.21470]

84 **Guadagnino V**, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, Carioti J, Maio G, Monarca R, Antinori A. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. *Addiction* 2007; **102**: 423-431 [PMID: 17298650 DOI: 10.1111/j.1360-0443.2006.01698.x]

85 **Grebely J**, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, McLean M, Mead A, Viljoen M, DeVlaming S, Fraser C, Conway B. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. *J Gastroenterol Hepatol* 2007; **22**: 1519-1525 [PMID: 17645460 DOI: 10.1111/j.1440-1746.2007.05032.x]

86 **Grebely J**, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, Raffa JD, DeVlaming S, Conway B. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. *Int J Drug Policy* 2007; **18**: 437-443 [PMID: 17854734 DOI: 10.1016/j.drugpo.2007.01.009]

87 **Schaefer M**, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M, Ziemer M, Gutsche J, Weich V, Halangk J, Berg T. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. *Hepatology* 2007; **46**: 991-998 [PMID: 17668880 DOI: 10.1002/hep.21791]

88 **Bruggmann P**, Falcato L, Dober S, Helbling B, Keiser O, Negro F, Meili D. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. *J Viral Hepat* 2008; **15**: 747-752 [PMID: 18637072 DOI: 10.1111/j.1365-2893.2008.01010.x]

89 **Papadopoulos V**, Gogou A, Mylopoulou T, Mimidis K. Should active injecting drug users receive treatment for chronic hepatitis C? *Arq Gastroenterol* ; **47**: 238-241 [PMID: 21140082 DOI: 10.1590/S0004-28032010000300005]

90 **Manolakopoulos S**, Deutsch MJ, Anagnostou O, Karatapanis S, Tiniakou E, Papatheodoridis GV, Georgiou E, Manesis E, Tzourmakliotis D, Archimandritis AJ. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. *Liver Int* 2010; **30**: 1454-1460 [PMID: 20846344 DOI: 10.1111/j.1478-3231.2010.02341.x]

91 **Wilkinson M**, Crawford V, Tippet A, Jolly F, Turton J, Sims E, Hekker M, Dalton J, Marley R, Foster GR. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. *Aliment Pharmacol Ther* 2009; **29**: 29-37 [PMID: 18752631 DOI: 10.1111/j.1365-2036.2008.03834.x]

92 **Jack K**, Willott S, Manners J, Varnam MA, Thomson BJ. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. *Aliment Pharmacol Ther* 2009; **29**: 38-45 [PMID: 18945252 DOI: 10.1111/j.1365-2036.2008.03872.x]

93 **Jafferbhoy H**, Miller MH, Dunbar JK, Tait J, McLeod S, Dillon JF. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. *J Viral Hepat* 2012; **19**: 112-119 [PMID: 22239500 DOI: 10.1111/j.1365-2893.2011.01446.x]

94 **Alvarez-Uria G**, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. *Liver Int* 2009; **29**: 1051-1055 [PMID: 19580634 DOI: 10.1111/j.1478-3231.2008.01958.x]

95 **Dimova RB**, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. *Clin Infect Dis* 2013; **56**: 806-816 [PMID: 23223596 DOI: 10.1093/cid/cis1007]

96 **Sasadeusz JJ**, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. *Addiction* 2011; **106**: 977-984 [PMID: 21205057 DOI: 10.1111/j.1360-0443.2010.03347.x]

97 **Jacobson IM**, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; **364**: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]

98 **Zeuzem S**, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; **364**: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]

99 **Poordad F**, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]

100 **Bacon BR**, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]

101 **van Heeswijk R**, Verboven P, Vandevoorde A, Vinck P, Snoeys J, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Witek J, Garg V. Pharmacokinetic interaction between telaprevir and methadone. *Antimicrob Agents Chemother* 2013; **57**: 2304-2309 [PMID: 23478952 DOI: 10.1128/AAC.02262-12]

102 **Luo X**, Trevejo J, van Heeswijk RP, Smith F, Garg V. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. *Antimicrob Agents Chemother* 2012; **56**: 3641-3647 [PMID: 22564847 DOI: 10.1128/AAC.00077-12]

103 **Arain A,** Bourgeois S, de Galocsy C, Deltenre P, d’Heygere F, Georges C, Bastens B, Van Overbeke L, Verrando R, Bruckers L, Mathei C, Buntinx F, Van Vlierberghe H, Francque S, Laleman W, Moreno C, Robaeys G. The Belgian experience in treatment of persons who used drugs with the new standard of care in genotype 1 HCV infected patients: an interim analysis. Abstract In: 3rd international symposium on hepatitis C care in substance users; 2013 Sept 5-6; Germany. Munich. Suchtmedizin; 2013: 228.

104 **Litwin AH,** Soloway IJ, Cockerham-Colas L, Reynoso S, Roose RJ. Successful treatmant of chronic hepatitis C with Direct-Acting Antiviral Agents in an opiate agonist treatment program. Abstract In: 3rd international symposium on hepatitis C care in substance users; 2013 Sept 5-6; Germany. Munich. Suchtmedizin; 2013: 227.

105 **Christensen S,** Naumann U, Gölz J. Triple therapy of chronic hepatitis C in opiate addicts-First results from 2 centres in Germany. Abstract In: 3rd international symposium on hepatitis C care in substance users; 2013 Sept 5-6; Germany. Munich. Suchtmedizin; 2013: 228.

106 **Grebely J**, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. *Curr Opin HIV AIDS* 2011; **6**: 501-507 [PMID: 22001894 DOI: 10.1097/COH.0b013e32834bcb36]

107 **Grebely J**, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, Kalousek K, Duncan F, Tyndall MW, Fraser C, Conway B, Fischer B. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. *Drug Alcohol Depend* 2008; **93**: 141-147 [PMID: 17997050 DOI: 10.1016/j.drugalcdep.2007.09.008]

108 **Treloar C**, Hull P, Bryant J, Hopwood M, Grebely J, Lavis Y. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. *Drug Alcohol Depend* 2011; **116**: 52-56 [PMID: 21194852 DOI: 10.1016/j.drugalcdep.2010.11.018]

109 **Treloar C**, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. *J Viral Hepat* 2010; **17**: 839-844 [PMID: 20070504 DOI: 10.1111/j.1365-2893.2009.01250.x]

110 **Doab A**, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. *Clin Infect Dis* 2005; **40** Suppl 5: S313-S320 [PMID: 15768340 DOI: 10.1086/427446]

111 **Kramer JR**, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. *Am J Gastroenterol* 2011; **106**: 483-491 [PMID: 21063393 DOI: 10.1038/ajg.2010.430]

112 **Gidding HF**, Law MG, Amin J, Macdonald GA, Sasadeusz JJ, Jones TL, Strasser SI, George J, Dore GJ. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. *Med J Aust* 2011; **194**: 398-402 [PMID: 21495939]

113 **Bini EJ**, Bräu N, Currie S, Shen H, Anand BS, Hu KQ, Jeffers L, Ho SB, Johnson D, Schmidt WN, King P, Cheung R, Morgan TR, Awad J, Pedrosa M, Chang KM, Aytaman A, Simon F, Hagedorn C, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki AW, Rossi S, Wright TL. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. *Am J Gastroenterol* 2005; **100**: 1772-1779 [PMID: 16086714 DOI: 10.1111/j.1572-0241.2005.41860.x]

114 **Kanwal F**, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, Goetz M, Asch SM. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. *Hepatology* 2007; **46**: 1741-1749 [PMID: 18046707 DOI: 10.1002/hep.21927]

115 **Aspinall EJ**, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. *Clin Infect Dis* 2013; **57** Suppl 2: S80-S89 [PMID: 23884071 DOI: 10.1093/cid/cit306]

116 **Hilsden RJ**, Macphail G, Grebely J, Conway B, Lee SS. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. *Clin Infect Dis* 2013; **57** Suppl 2: S90-S96 [PMID: 23884072 DOI: 10.1093/cid/cit327]

117 **Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06102-5]

118 **Fried MW,** Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]

119 **Talal AH,** Dimova RB, Seewald R, Peterson RH, Zeremski M, Perlman DC, Des Jarlais DC. Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. *J Subst Abuse Treat* 2013; **44**:115-119 [PMID: 22405884 DOI: 10.1016/j.jsat.2012.01.010]

120 **Sylvestre DL**, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. *Eur J Gastroenterol Hepatol* 2007; **19**: 741-747 [PMID: 17700258 DOI: 10.1097/MEG.0b013e3281bcb8d8]

121 **Gazdik F**, Gazdikova K, Laktis K, Okruhlica L, Fejdiova K, Danis D, Pijak MR, Wsolova L, Kajaba I, Kratky A. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin. *Bratisl Lek Listy* 2009; **110**: 77-84 [PMID: 19408838]

122 **Bonkovsky HL**, Tice AD, Yapp RG, Bodenheimer HC, Monto A, Rossi SJ, Sulkowski MS. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. *Am J Gastroenterol* 2008; **103**: 2757-2765 [PMID: 18684176 DOI: 10.1111/j.1572-0241.2008.02065.x]

123 **Schulte B**, Schütt S, Brack J, Isernhagen K, Deibler P, Dilg C, Verthein U, Haasen C, Reimer J. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. *Drug Alcohol Depend* 2010; **109**: 248-251 [PMID: 20167441 DOI: 10.1016/j.drugalcdep.2010.01.009]

124 **Bruggmann P**. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. *J Viral Hepat* 2012; **19**: 829-835 [PMID: 23205675 DOI: 10.1111/jvh.12008]

125 **Reimer J**, Haasen C. Need-adapted HCV-treatment setting for injection drug users. *Lancet* 2009; **373**: 2090-2091 [PMID: 19376573 DOI: 10.1016/S0140-6736(09)60347-0]

126 **Litwin AH**, Kunins HV, Berg KM, Federman AD, Heavner KK, Gourevitch MN, Arnsten JH. Hepatitis C management by addiction medicine physicians: results from a national survey. *J Subst Abuse Treat* 2007; **33**: 99-105 [PMID: 17379472 DOI: 10.1016/j.jsat.2006.12.001]

127 **Bini EJ**, Kritz S, Brown LS, Robinson J, Alderson D, Rotrosen J. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. *J Addict Dis* 2011; **30**: 98-109 [PMID: 21491291 DOI: 10.1080/10550887.2011.554780]

128 **Mehta SH**, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. *J Community Health* 2008; **33**: 126-133 [PMID: 18165889 DOI: 10.1007/s10900-007-9083-3]

129 **Gupta L**, Shah S, Ward JE. Educational and health service needs of Australian general practitioners in managing hepatitis C. *J Gastroenterol Hepatol* 2006; **21**: 694-699 [PMID: 16677155 DOI: 10.1111/j.1440-1746.2006.04205.x]

130 **Clark EC**, Yawn BP, Galliher JM, Temte JL, Hickner J. Hepatitis C identification and management by family physicians. *Fam Med* 2005; **37**: 644-649 [PMID: 16193428]

131 **Cullen W**, Stanley J, Langton D, Kelly Y, Staines A, Bury G. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. *Br J Gen Pract* 2006; **56**: 848-856 [PMID: 17132352]

132 **Chossegros P**, Mélin P, Hézode C, Bourlière M, Pol S, Fhima A, Filoche B, Trépo C, Couzigou P, Ouzan D, Gagnon A. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers. *Gastroenterol Clin Biol* 2008; **32**: 850-857 [PMID: 18805662 DOI: 10.1016/j.gcb.2008.07.004]

133 **Treloar C**, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. *Clin Infect Dis* 2013; **57** Suppl 2: S51-S55 [PMID: 23884066 DOI: 10.1093/cid/cit263]

134 **Link BG**, Struening EL, Rahav M, Phelan JC, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. *J Health Soc Behav* 1997; **38**: 177-190 [PMID: 9212538 DOI: 10.2307/2955424]

135 **Fife BL**, Wright ER. The dimensionality of stigma: a comparison of its impact on the self of persons with HIV/AIDS and cancer. *J Health Soc Behav* 2000; **41**: 50-67 [PMID: 10750322 DOI: 10.2307/2676360]

136 **Van Brakel WH**. Measuring health-related stigma--a literature review. *Psychol Health Med* 2006; **11**: 307-334 [PMID: 17130068 DOI: 10.1080/13548500600595160]

137 **Earnshaw VA**, Quinn DM. The impact of stigma in healthcare on people living with chronic illnesses. *J Health Psychol* 2012; **17**: 157-168 [PMID: 21799078 DOI: 10.1177/1359105311414952]

138 **Golden J**, Conroy RM, O'Dwyer AM, Golden D, Hardouin JB. Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. *Soc Sci Med* 2006; **63**: 3188-3198 [PMID: 17010490 DOI: 10.1016/j.socscimed.2006.08.005]

139 **Crockett B**, Gifford SM. "Eyes Wide Shut": narratives of women living with hepatitis C in Australia. *Women Health* 2004; **39**: 117-137 [PMID: 15691088 DOI: 10.1300/J013v39n04\_07]

140 **Spiegel BM**, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. *Hepatology* 2005; **41**: 790-800 [PMID: 15791608 DOI: 10.1002/hep.20659]

141 **Ahern J**, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. *Drug Alcohol Depend* 2007; **88**: 188-196 [PMID: 17118578 DOI: 10.1016/j.drugalcdep.2006.10.014]

142 **Miller ER**, McNally S, Wallace J, Schlichthorst M. The ongoing impacts of hepatitis c--a systematic narrative review of the literature. *BMC Public Health* 2012; **12**: 672 [PMID: 22900973 DOI: 10.1186/1471-2458-12-672]

143 **Zickmund S**, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. *J Gen Intern Med* 2003; **18**: 835-844 [PMID: 14521647 DOI: 10.1046/j.1525-1497.2003.20826.x]

144 **Hall MA**, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? *Milbank Q* 2001; **79**: 613-39, v [PMID: 11789119 DOI: 10.1111/1468-0009.00223]

145 **Curcio F**, Di Martino F, Capraro C, Angelucci F, Bulla F, Caprio N, Cascone A, D'ascoli G, Focaccio F, Gaveglia M, Longobardo A, Martini S, Masucci S, Morra A, Pasquale G, Pisapia R, Plenzik M, Veneruso C, Villano G, Russo M, De Rosa G, Filippini P. Together … to take care: multidisciplinary management of hepatitis C virus treatment in randomly selected drug users with chronic hepatitis. *J Addict Med* 2010; **4**: 223-232 [PMID: 21769040 DOI: 10.1097/ADM.0b013e3181cae4d0]

146 **Litwin AH**, Harris KA, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. *J Subst Abuse Treat* 2009; **37**: 32-40 [PMID: 19038524 DOI: 10.1016/j.jsat.2008.09.009]

147 **Belfiori B**, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, Francisci D. Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. *Dig Liver Dis* 2009; **41**: 303-307 [PMID: 18938116 DOI: 10.1016/j.dld.2008.08.009]

148 **Hill WD**, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. *Can J Gastroenterol* 2008; **22**: 27-32 [PMID: 18209777]

149 **Seidenberg A**, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. *BMC Infect Dis* 2013; **13**: 9 [PMID: 23298178 DOI: 10.1186/1471-2334-13-9]

150 **Harris KA**, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. *J Addict Med* 2010; **4**: 20-26 [PMID: 20485532 DOI: 10.1097/ADM.0b013e3181add3de]

151 **Charlebois A**, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. *J Viral Hepat* 2012; **19**: 836-842 [PMID: 23121361 DOI: 10.1111/j.1365-2893.2012.01648.x]

152 **Schaefer M**, Sarkar R, Diez-Quevedo C. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. *Clin Infect Dis* 2013; **57** Suppl 2: S111-S117 [PMID: 23884058 DOI: 10.1093/cid/cit266]

153 **Evon DM**, Simpson K, Kixmiller S, Galanko J, Dougherty K, Golin C, Fried MW. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. *Am J Gastroenterol* 2011; **106**: 1777-1786 [PMID: 21769136 DOI: 10.1038/ajg.2011.219]

154 **Reimer J**, Schmidt CS, Schulte B, Gansefort D, Gölz J, Gerken G, Scherbaum N, Verthein U, Backmund M. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial. *Clin Infect Dis* 2013; **57** Suppl 2: S97-104 [PMID: 23884073 DOI: 10.1093/cid/cit307]

155 **Larrey D**, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B, Pageaux GP, Vaucher E, Arpurt JP, Boulay G, Karlova N, Daures JP. Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirin. *Clin Gastroenterol Hepatol* 2011; **9**: 781-785 [PMID: 21683161 DOI: 10.1016/j.cgh.2011.05.022]

156 **Knott A**, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR, Thuras P, Ho SB. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. *Am J Gastroenterol* 2006; **101**: 2254-2262 [PMID: 17032190 DOI: 10.1111/j.1572-0241.2006.00731.x]

157 **Lloyd AR**, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, Boonwaat L, Forrest G, Douglas J, Monkley D. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. *Clin Infect Dis* 2013; **56**: 1078-1084 [PMID: 23362288 DOI: 10.1093/cid/cis1202]

158 **Stein MR**, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. *J Subst Abuse Treat* 2012; **43**: 424-432 [PMID: 23036920 DOI: 10.1016/j.jsat.2012.08.007]

159 **Bruggmann P**, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. *Clin Infect Dis* 2013; **57** Suppl 2: S56-S61 [PMID: 23884067 DOI: 10.1093/cid/cit271]

160 **Crawford S**, Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. *Clin Infect Dis* 2013; **57** Suppl 2: S75-S79 [PMID: 23884070 DOI: 10.1093/cid/cit297]

161 **Ti L**, Kaplan K, Hayashi K, Suwannawong P, Wood E, Kerr T. Low rates of hepatitis C testing among people who inject drugs in Thailand: implications for peer-based interventions. *J Public Health (Oxf)* 2013; **35**: 578-584 [PMID: 23335599 DOI: 10.1093/pubmed/fds105]

162 **Sylvestre DL**, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. *Int J Drug Policy* 2007; **18**: 406-410 [PMID: 17854729 DOI: 10.1016/j.drugpo.2007.01.010]

163 **Latka MH**, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell JV, Coady MH, Garfein RS, Pu M, Thomas DL, Thiel TK, Strathdee SA. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. *Am J Public Health* 2008; **98**: 853-861 [PMID: 18382005 DOI: 10.2105/AJPH.2007.113415]

164 **Garfein RS**, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, Kapadia F, Latka MH, Ouellet LJ, Purcell DW, Strathdee SA, Thiede H. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. *AIDS* 2007; **21**: 1923-1932 [PMID: 17721100 DOI: 10.1097/QAD.0b013e32823f9066]

165 **Mackesy-Amiti ME**, Finnegan L, Ouellet LJ, Golub ET, Hagan H, Hudson SM, Latka MH, Garfein RS. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. *AIDS Behav* 2013; **17**: 2075-2083 [PMID: 23142857 DOI: 10.1007/s10461-012-0373-0]

166 **Martin NK**, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. *BMJ Open* 2013; **3**: [PMID: 23943776 DOI: 10.1136/bmjopen-2013-003153]

167 **Martin NK**, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology* 2013; **58**: 1598-1609 [PMID: 23553643 DOI: 10.1002/hep.26431]

168 **Visconti AJ**, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. *J Gastroenterol Hepatol* 2013; **28**: 707-716 [PMID: 23173753 DOI: 10.1111/jgh.12041]

169 **Fazel S**, Baillargeon J. The health of prisoners. *Lancet* 2011; **377**: 956-965 [PMID: 21093904 DOI: 10.1016/S0140-6736(10)61053-7]

170 **Vescio MF**, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, Monarca R. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *J Epidemiol Community Health* 2008; **62**: 305-313 [PMID: 18339822 DOI: 10.1136/jech.2006.051599]

171 **Hickman M**, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, Parry JV. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. *J Viral Hepat* 2008; **15**: 250-254 [PMID: 18086182 DOI: 10.1111/j.1365-2893.2007.00937.x]

172 **Elger B,** Ritter C, Stöver H. Emerging Issues in Prison Health Springer: Heidelberg/New York (In press).

173 **Post JJ**, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting. *Clin Infect Dis* 2013; **57** Suppl 2: S70-S74 [PMID: 23884069 DOI: 10.1093/cid/cit265]

174 **Grady BP**, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. *Clin Infect Dis* 2013; **57 Suppl 2**: S105-S110 [PMID: 23884057 DOI: 10.1093/cid/cit301]

175 **Page K**, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. *Clin Infect Dis* 2013; **57** Suppl 2: S32-S38 [PMID: 23884063 DOI: 10.1093/cid/cit300]

176 **Martin NK**, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. *Clin Infect Dis* 2013; **57** Suppl 2: S39-S45 [PMID: 23884064 DOI: 10.1093/cid/cit296]

177 **Bruggmann P**. Treatment as prevention: the breaking of taboos is required in the fight against hepatitis C among people who inject drugs. *Hepatology* 2013; **58**: 1523-1525 [PMID: 23728921 DOI: 10.1002/hep.26539]

178 **Kautz A.** Personal communication at 3rd international symposium on hepatitis C care in substance users. Munich: 2013: Sept 5-6.

**P-Reviewers:** Chetty R, Kim JS, Pantopoulos K, Zeisel MB

**S-Editor:** Qi Y **L-Editor: E-Editor:**